Enzalutamide by Pfizer for Peritoneal Cancer: Likelihood of Approval

Enzalutamide is under clinical development by Pfizer and currently in Phase II for Peritoneal Cancer.

Dec 24, 2023 - 18:00

Enzalutamide is under clinical development by Pfizer and currently in Phase II for Peritoneal Cancer.

Read the original article

Tags:

Previous Article

(Curcumin + doxorubicin) by Immix BioPharma for Colorectal Cancer: Likelihood of...

Enzalutamide by Pfizer for Fallopian Tube Cancer: Likelihood of Approval

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

STAT+: How doctors and nurses shape Google’s AI, DEA extends telehealth flexibilities

STAT+: How doctors and nurses shape Google’s AI, DEA ex...

Oct 10, 2023

ABBV-444 by AbbVie for Keratoconjunctivitis Sicca (Dry ...

Jul 1, 2023

Failed clinical trials don’t always spell doom for a new drug. Here’s why

Failed clinical trials don’t always spell doom for a ne...

Aug 9, 2023